Evaluation of IPW-5371, a tgfbri kinase inhibitor, dosed as a single agent or in combination with G-CSF, as a medical countermeasure against the delayed effects of total body irradiation in mice
Ended Project Grant Awarded Last action
- Award ID
- R43AI138868
- Recipient
-
Innovation Pathways, LLC UEI NAHEV73JLXH3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,969
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Palo Alto, CA 94301, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$31 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $300,000 | |
| Original award | $300,000 |
Quick answers
Who received award R43AI138868?
R43AI138868 was awarded to Innovation Pathways, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 14, 2018.
How much is award R43AI138868 worth?
$599,969 has been obligated on R43AI138868.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award